Zepbound produces roughly twice as much weight loss as Foundayo in clinical trials (about 22% vs. 11% of body weight). It works on two hormone pathways (GIP and GLP-1) and is given as a weekly injection. Foundayo is an oral once-daily pill — no injections, no food or water restrictions — making it the most convenient GLP-1 option available. Both are made by Eli Lilly, have similar GI side effects, and work best as an adjunct to diet and exercise. Your provider can help you decide which trade-off matters most.
Foundayo and Zepbound are both FDA-approved weight loss medications from the same manufacturer, Eli Lilly. But they’re very different in how they work, how you take them, and how much weight they help you lose.
At PEAK Wellness & Aesthetics, we prescribe both. This guide covers the real differences so you can have an informed conversation with your provider.
How they work: pill vs. injection, one pathway vs. two
The most obvious difference is how you take them — but the mechanism differences matter too.
Foundayo (orforglipron) is an oral tablet you take once a day. It’s a small-molecule (non-peptide) GLP-1 receptor agonist, meaning it mimics the gut hormone GLP-1 to reduce appetite, signal fullness, and slow digestion. Unlike older oral GLP-1 medications, Foundayo has no food or water restrictions — you can take it any time of day with or without food.
Zepbound (tirzepatide) is a once-weekly subcutaneous injection. It’s a dual GIP and GLP-1 receptor agonist, meaning it activates two gut hormone pathways instead of one. GIP appears to enhance the appetite-suppressing and metabolic effects of GLP-1, which likely explains why Zepbound produces greater weight loss in clinical trials.
In short: Foundayo offers the convenience of a daily pill with one hormone pathway. Zepbound offers greater efficacy with two hormone pathways but requires a weekly injection.
Weight loss: what the studies show
These medications have not been tested head-to-head, so we’re comparing results from separate clinical trials. Cross-trial comparisons have limitations, but they give us a reasonable picture of how these medications stack up.
Results at 72 weeks
| Outcome | Foundayo (17.2 mg) | Zepbound (15 mg) |
|---|---|---|
| Average weight loss | ~11% | ~22.5% |
| Average pounds lost | ~25 lbs | ~50 lbs |
| Achieved ≥10% loss | ~55% | ~80% |
| How you take it | Daily oral tablet | Weekly injection |
| Key trial | ATTAIN-1 | SURMOUNT-1 |
Sources: ATTAIN-1 (Foundayo 17.2 mg, 72 weeks) and SURMOUNT-1 (Zepbound 15 mg, 72 weeks). Different trial populations — not a head-to-head comparison. Individual results vary.
The weight loss difference is substantial. Zepbound users lost roughly twice as much body weight as Foundayo users at their respective maximum approved doses. This is consistent with what we’d expect from a dual-mechanism injectable vs. a single-mechanism oral pill.
That said, ~11% body weight loss is still clinically meaningful. For a 230-pound patient, that’s about 25 pounds — enough to improve blood pressure, blood sugar, and quality of life. Not everyone needs maximum weight loss to achieve their health goals.
Side effects: similar GI profiles
Both medications cause similar gastrointestinal side effects. This is expected since they both act on GLP-1 receptors.
The most common side effects for both include nausea, diarrhea, constipation, and indigestion. In the ATTAIN-1 trial, about 35% of patients taking Foundayo at the highest dose experienced nausea. Zepbound has a comparable GI side effect profile.
These side effects are typically mild to moderate and tend to improve over time, especially as your body adjusts during the dose escalation period.
Both medications carry a boxed warning about thyroid C-cell tumors based on findings with other GLP-1 receptor agonists in rodents. Orforglipron (Foundayo) itself did not produce thyroid C-cell tumors in animal studies; the warning is a class-level precaution. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The side effect profiles are similar enough that the choice between Foundayo and Zepbound usually comes down to convenience vs. efficacy — not tolerability.
Dosing: daily pill vs. weekly injection
The dosing schedules differ significantly — not just in frequency, but in the number of dose steps.
| Feature | Foundayo (orforglipron) | Zepbound (tirzepatide) |
|---|---|---|
| Route | Oral tablet | Subcutaneous injection |
| Frequency | Once daily | Once weekly |
| Food restrictions | None | N/A (injection) |
| Available doses | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Dose steps | 6 doses | 6 doses |
| Max approved dose | 17.2 mg | 15 mg |
Foundayo starts at a low dose (0.8 mg) and gradually increases. The lack of food or water restrictions is a notable advantage — you simply take a pill at whatever time works for you.
Zepbound also titrates gradually, starting at 2.5 mg weekly. The injection is administered with a pre-filled pen, similar to an insulin pen. Most patients find the injections straightforward after the first one.
FDA approvals: new vs. established
Both medications are FDA-approved for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.
Foundayo
- FDA approved April 2026 for chronic weight management
- Brand new to market — limited real-world data beyond clinical trials
Zepbound
- FDA approved November 2023 for chronic weight management
- Also approved for moderate-to-severe obstructive sleep apnea in adults with obesity
- More than two years of real-world prescribing data and a larger body of clinical evidence
Zepbound’s longer track record gives providers more confidence in its safety profile and real-world effectiveness. Foundayo is brand new, and while its clinical trial data is solid, real-world experience will take time to accumulate.
Insurance coverage & cost
Insurance coverage for weight loss medications generally requires prior authorization. Because Foundayo is newly approved, many insurance formularies may not yet include it. Coverage will likely expand over time.
At PEAK, we check your benefits before your first visit and help you understand which medications your plan covers. If one is denied, we can try alternatives.
Self-pay pricing
Both medications are available through LillyDirect, Eli Lilly’s direct-to-patient pharmacy program:
- Foundayo: $149–$299/month via LillyDirect; savings card for commercial insurance may lower cost to as low as $25/month (subject to caps; not valid for government insurance)
- Zepbound: $399–$549/month via LillyDirect; savings card available for eligible patients with commercial insurance
Foundayo’s lower self-pay price point may make it more accessible for patients paying out of pocket. Pricing is set by the manufacturer and subject to change.
Learn more about insurance coverage for weight loss medications →
Related: Foundayo Savings Card: Eligibility & How to Apply • Foundayo (Orforglipron): What You Need to Know
How to choose: a decision framework
- You prefer a daily pill over injections
- Needle aversion is a barrier to starting treatment
- You want a lower self-pay cost
- Moderate weight loss (~11%) aligns with your health goals
- You value the convenience of no food or water restrictions
- Maximum weight loss is your primary goal
- You’re comfortable with a weekly injection
- You have obstructive sleep apnea
- You want a medication with a longer real-world track record
- Your insurance covers Zepbound
There’s no single right answer. Some patients prioritize convenience and start with Foundayo. Others want the strongest possible weight loss and choose Zepbound. For a broader look at all your options, see our guide on how to choose a weight loss medication.
What about switching between them?
Switching from Foundayo to Zepbound (or vice versa) should be done under medical supervision. Your dose and timing will need to be adjusted during the transition.
Reasons patients might switch include wanting more weight loss after starting with the oral option, preferring a pill after experiencing injection fatigue, insurance coverage changes, or side effect differences.
This flexibility is one of the benefits of working with a medical weight loss clinic that prescribes multiple medications. We can adjust your treatment plan based on how you’re responding — not just write one prescription and hope for the best. Our registered dietitian also works alongside your provider to support your results.
Can I take both together?
No. You should not take Foundayo and Zepbound at the same time. Both act on GLP-1 receptors, and combining them would increase the risk of side effects without additional benefit. You take one or the other.
